No dedicated clinical interaction studies have been performed.
Clinical experience has not given evidence for potential interaction of Recormon with other medicinal products (for more information see also Pharmacology: Toxicology: Nonclinical Safety: Other under Actions).
In animal experiments epoetin did not increase the myelotoxicity of cytostatic medicinal products like etoposide, cisplatin, cyclophosphamide and fluorouracil.